Stephen P. Carey, SVP and CFO of ANI Pharmaceuticals Inc, filed a Form 4 on October 30, 2026, disclosing the sale of 2,850 shares of common stock on October 29, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Stephen P. Carey, SVP and CFO of ANI Pharmaceuticals Inc (NASDAQ:ANIP)
  • Shares disposed: 2,850 shares of common stock sold on October 29, 2026
  • Weighted average price: $72.87 per share, with individual trades ranging from $72.18 to $73.29
  • Beneficial ownership after transaction: 166,143 shares held directly
  • Trading plan: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Carey on March 6, 2026
  • Transaction code: S (sale), reported as a direct holding

Stephen P. Carey's October 2026 Share Sale Under 10b5-1 Plan

According to the filing, Stephen P. Carey, serving as SVP and CFO of ANI Pharmaceuticals Inc, disposed of 2,850 shares of the company's common stock on October 29, 2026. The transaction was carried out under transaction code "S," indicating an open-market sale. The shares were sold in multiple trades at prices ranging from $72.18 to $73.29, and the filing reports a weighted average sales price of $72.87 per share.

The filing notes that the sales were made pursuant to a Rule 10b5-1 trading plan that Carey adopted on March 6, 2026. The Form 4 box indicating a transaction made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) was checked. Following the reported transaction, Carey's direct beneficial ownership in ANI Pharmaceuticals common stock stands at 166,143 shares, according to the filing.

The Form 4 was signed by Meredith W. Cook as attorney-in-fact for Stephen P. Carey and filed with the SEC on October 30, 2026. No derivative securities transactions were reported in this filing. The filing lists Carey's address as c/o ANI Pharmaceuticals, Inc., 104 Carnegie Center, Suite 300, Princeton, New Jersey 08540.

What Was Disclosed

ANI Pharmaceuticals CFO Stephen P. Carey reported the sale of 2,850 shares of common stock on October 29, 2026, at a weighted average price of $72.87, executed under a Rule 10b5-1 plan adopted March 6, 2026, leaving him with 166,143 shares directly held.